Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lung Immune Challenge Study with Inhaled Resiquimod (R848)
NCT06488118Recruiting
- Start
- May 2024
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of resiquimod (8 arms). Primary endpoint: Change in Serum or Sputum CXCL10 at 24 hours. Started May 2024; status: recruiting.
02
Drugs
resiquimod
Beyond the preview
Go deeper on NCT06488118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06488118.